These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25793878)

  • 1. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
    Vick B; Rothenberg M; Sandhöfer N; Carlet M; Finkenzeller C; Krupka C; Grunert M; Trumpp A; Corbacioglu S; Ebinger M; André MC; Hiddemann W; Schneider S; Subklewe M; Metzeler KH; Spiekermann K; Jeremias I
    PLoS One; 2015; 10(3):e0120925. PubMed ID: 25793878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to establish acute myeloid leukemia xenograft models using immunodeficient mice.
    Shan WL; Ma XL
    Asian Pac J Cancer Prev; 2013; 14(12):7057-63. PubMed ID: 24460250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.
    Saland E; Boutzen H; Castellano R; Pouyet L; Griessinger E; Larrue C; de Toni F; Scotland S; David M; Danet-Desnoyers G; Vergez F; Barreira Y; Collette Y; Récher C; Sarry JE
    Blood Cancer J; 2015 Mar; 5(3):e297. PubMed ID: 25794133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 5. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells.
    Kawashima N; Ishikawa Y; Kim JH; Ushijima Y; Akashi A; Yamaguchi Y; Hattori H; Nakashima M; Ikeno S; Kihara R; Nishiyama T; Morishita T; Watamoto K; Ozawa Y; Kitamura K; Kiyoi H
    Nat Commun; 2022 Mar; 13(1):1624. PubMed ID: 35338146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.
    Her Z; Yong KSM; Paramasivam K; Tan WWS; Chan XY; Tan SY; Liu M; Fan Y; Linn YC; Hui KM; Surana U; Chen Q
    J Hematol Oncol; 2017 Oct; 10(1):162. PubMed ID: 28985760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the In Vivo Role of Candidate Leukemia Stem Cell Genes.
    Zhang YW; Mess J; Cabezas-Wallscheid N
    Methods Mol Biol; 2021; 2185():307-316. PubMed ID: 33165857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice.
    Ailles LE; Humphries RK; Thomas TE; Hogge DE
    Exp Hematol; 1999 Nov; 27(11):1609-20. PubMed ID: 10560908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.
    Carretta M; de Boer B; Jaques J; Antonelli A; Horton SJ; Yuan H; de Bruijn JD; Groen RWJ; Vellenga E; Schuringa JJ
    Exp Hematol; 2017 Jul; 51():36-46. PubMed ID: 28456746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.
    Terziyska N; Castro Alves C; Groiss V; Schneider K; Farkasova K; Ogris M; Wagner E; Ehrhardt H; Brentjens RJ; zur Stadt U; Horstmann M; Quintanilla-Martinez L; Jeremias I
    PLoS One; 2012; 7(12):e52798. PubMed ID: 23300782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies.
    Gelebart P; Popa M; McCormack E
    Curr Pharm Biotechnol; 2016; 17(1):42-51. PubMed ID: 26278528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients.
    Ali MA; Naka K; Yoshida A; Fuse K; Kasada A; Hoshii T; Tadokoro Y; Ueno M; Ohta K; Kobayashi M; Takahashi C; Hirao A
    Biochem Biophys Res Commun; 2014 Jul; 450(1):837-43. PubMed ID: 24960197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
    Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
    Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells.
    Schuringa JJ; Schepers H
    Methods Mol Biol; 2009; 538():287-300. PubMed ID: 19277587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.